Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Return on Sales (2020 - 2023)

Historic Return on Sales for ADC Therapeutics (ADCT) over the last 5 years, with Q4 2023 value amounting to 2.91%.

  • ADC Therapeutics' Return on Sales fell 29100.0% to 2.91% in Q4 2023 from the same period last year, while for Dec 2023 it was 2.91%, marking a year-over-year decrease of 29100.0%. This contributed to the annual value of 0.73% for FY2022, which is 65947300.0% up from last year.
  • Latest data reveals that ADC Therapeutics reported Return on Sales of 2.91% as of Q4 2023, which was down 29100.0% from 3.13% recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Return on Sales ranged from a high of 0.0% in Q4 2022 and a low of 140234.48% during Q3 2020
  • Moreover, its 5-year median value for Return on Sales was 8.61% (2021), whereas its average is 7975.29%.
  • As far as peak fluctuations go, ADC Therapeutics' Return on Sales crashed by -1402129900bps in 2020, and later skyrocketed by 1402290600bps in 2021.
  • Over the past 5 years, ADC Therapeutics' Return on Sales (Quarter) stood at 157.91% in 2019, then plummeted by -88709bps to 140234.48% in 2020, then soared by 100bps to 33.5% in 2021, then soared by 100bps to 0.0% in 2022, then tumbled by -1251162430bps to 2.91% in 2023.
  • Its Return on Sales stands at 2.91% for Q4 2023, versus 3.13% for Q3 2023 and 2.5% for Q2 2023.